BCYC — Bicycle Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $644.06m
- -$147.93m
- $35.28m
- 60
- 20
- 17
- 23
Annual cashflow statement for Bicycle Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51 | -66.8 | -113 | -181 | -169 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 6.59 | 12.6 | 27.2 | 33.5 | 35.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 25.4 | 38.1 | 0.672 | 76.7 | -33.4 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -17.8 | -14.8 | -86.1 | -60.6 | -165 |
| Capital Expenditures | -1.2 | -2.03 | -19 | -2.93 | -1.24 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -1.2 | -2.03 | -19 | -2.93 | -1.24 |
| Financing Cash Flow Items | -0.573 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 62.8 | 321 | 6.69 | 250 | 520 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 43.9 | 303 | -99.5 | 188 | 353 |